Simris Group targets late 2027/early 2028 clinical entry for two amanitin-based ADC programs

• Simris Group set a strategy to prioritize amanitin-derived ADC payloads to address treatment resistance in liquid and solid tumors.
• Targets two proprietary amanitin-based ADC candidates, SMR-101 and SMR-102, for clinical entry in late 2027 or early 2028.
• Operations will center on an amanitin ADC platform, with Simris Biologics as the main development vehicle under CEO Andreas Pahl.
• Plans to add six ADC development specialists over the next 12 months to accelerate manufacturing, regulatory, and clinical readiness.
• Microcystin-based ADC work continues in parallel, with ongoing studies aimed at generating in vivo safety and efficacy data.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Simris Group AB published the original content used to generate this news brief on September 08, 2026, and is solely responsible for the information contained therein.